Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 21:00 UTC |
Caragol William JChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 212,500 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001213900-26-088447 · ownership.xml · derivative · entry 1 Caragol William J · CIK 0001380465 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,500 Underlying: Ordinary Shares · 212,500 shares Expires 2036-08-11 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionSeries D Preferred Shares · Derivative | 124,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · derivative · entry 8 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,300 Underlying: Ordinary Shares · 28,057,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · derivative.exercise_date: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2 · derivative.expiration_date: Each class of Preferred Shares is perpetual and therefore has no expiration date. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionSeries C Preferred Shares · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · derivative · entry 7 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · derivative.exercise_date: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2 · derivative.expiration_date: Each class of Preferred Shares is perpetual and therefore has no expiration date. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionSeries B Preferred Shares · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · derivative · entry 6 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · derivative.exercise_date: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2 · derivative.expiration_date: Each class of Preferred Shares is perpetual and therefore has no expiration date. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionSeries A Preferred Shares · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · derivative · entry 5 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · price: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F1 · derivative.exercise_date: Following receipt by Quantum Cyber N.V. (the "Company") of stockholder approval on April 22, 2026, each class of Preferred Shares became convertible into Ordinary Shares at the option of David E. Lazar (the "Reporting Person") for no additional consideration. On August 5, 2026, the Reporting Person submitted notices of conversion to convert all of his Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares, and 124,700 of his Series D Preferred Shares, into Ordinary Shares. F2 · derivative.expiration_date: Each class of Preferred Shares is perpetual and therefore has no expiration date. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionOrdinary Shares | 28,057,500 | $225.00 | $6,312,937,500.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · nonDerivative · entry 4 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,057,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionOrdinary Shares | 9,000,000 | $9.00 | $81,000,000.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · nonDerivative · entry 3 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionOrdinary Shares | 9,000,000 | $9.00 | $81,000,000.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · nonDerivative · entry 2 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:51 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
ConversionOrdinary Shares | 9,000,000 | $9.00 | $81,000,000.00 |
DisclosureSEC source: 0001829126-26-008488 · ownership.xml · nonDerivative · entry 1 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:42 UTC |
O'Rourke PeterDirector
|
GrantStock Option (Right to Buy) · Derivative | 190,840 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-085337 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,840 Underlying: Ordinary Shares · 190,840 shares Expires 2036-08-03 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:41 UTC |
NATAN DAVIDDirector
|
GrantStock Option (Right to Buy) · Derivative | 190,840 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-085336 · ownership.xml · derivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,840 Underlying: Ordinary Shares · 190,840 shares Expires 2036-08-03 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:40 UTC |
Caragol William JChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 212,500 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-085335 · ownership.xml · derivative · entry 1 Caragol William J · CIK 0001380465 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,500 Underlying: Ordinary Shares · 212,500 shares Expires 2036-08-03 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 31, 2026 Filed Aug 5, 2026 00:39 UTC |
Buffalino Louis R.Director
|
GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-085334 · ownership.xml · derivative · entry 1 Buffalino Louis R. · CIK 0001797586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Ordinary Shares · 425,000 shares Expires 2036-08-03 F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 31, 2026 Filed Aug 6, 2026 01:35 UTC |
Ben-Tzvi AvrahamDirector
|
GrantOrdinary Shares | 112,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-085872 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,400 Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:51 UTC Amendment |
Ben-Tzvi AvrahamDirector
|
GrantOrdinary Shares | 112,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-086310 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:53 UTC Amendment |
O'Rourke PeterDirector
|
GrantStock Option (Right to Buy) · Derivative | 191,860 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-086314 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,860 Underlying: Ordinary Shares · 191,860 shares Expires 2036-08-03 F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. F1 · derivative.underlying_shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:52 UTC Amendment |
NATAN DAVIDDirector
|
GrantStock Option (Right to Buy) · Derivative | 191,860 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-086313 · ownership.xml · derivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,860 Underlying: Ordinary Shares · 191,860 shares Expires 2036-08-03 F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. F1 · derivative.underlying_shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:52 UTC Amendment |
Caragol William JChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 212,500 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-086312 · ownership.xml · derivative · entry 1 Caragol William J · CIK 0001380465 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,500 Underlying: Ordinary Shares · 212,500 shares Expires 2036-08-03 F1 · date: The purpose of this Form 4/A is to correct the date of the reported transaction. F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 22, 2026 Filed Aug 6, 2026 23:52 UTC Amendment |
Buffalino Louis R.Director
|
GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-26-086311 · ownership.xml · derivative · entry 1 Buffalino Louis R. · CIK 0001797586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Ordinary Shares · 425,000 shares Expires 2036-08-03 F1 · date: The purpose of this Form 4/A is to correct the date of the reported transaction. F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 10:02 UTC |
O'Rourke PeterDirector
|
GrantStock Option (Right to Buy) · Derivative | 112,859 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001213900-26-075719 · ownership.xml · derivative · entry 1 O'Rourke Peter · CIK 0001890749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,859 Underlying: Ordinary Shares · 112,859 shares Expires 2036-07-06 Read SEC document |
| May 08, 2026 Filed May 21, 2026 23:07 UTC |
NATAN DAVIDDirector
|
GrantOrdinary Shares | 137,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060214 · ownership.xml · nonDerivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,141 Read SEC document |
| May 08, 2026 Filed May 26, 2026 22:12 UTC |
Ben-Tzvi AvrahamDirector
|
GrantOrdinary Shares | 137,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-061129 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,141 Read SEC document |
| April 22, 2026 Filed Apr 28, 2026 21:39 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
GrantSeries E Preferred Shares · Derivative | 1,000,000 | $1.50 | $1,500,000.00 |
DisclosureSEC source: 0000921895-26-001100 · form412227qucy_04232026.xml · derivative · entry 3 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 225,000,000 shares Expires not disclosed F2 · security: As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · security: On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. F4 · derivative.exercise_price: The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. F2 · price: As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · derivative.exercise_date: On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. F5 · derivative.expiration_date: Each class of Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| April 22, 2026 Filed Apr 28, 2026 21:39 UTC |
Lazar David E.Director · Chief Executive Officer · 10% owner
|
GrantSeries D Preferred Shares · Derivative | 1,000,000 | $1.50 | $1,500,000.00 |
DisclosureSEC source: 0000921895-26-001100 · form412227qucy_04232026.xml · derivative · entry 2 Lazar David E. · CIK 0001932843 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 225,000,000 shares Expires not disclosed F2 · security: As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · security: On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. F4 · derivative.exercise_price: The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. F2 · price: As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · derivative.exercise_date: On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. F5 · derivative.expiration_date: Each class of Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 22:17 UTC |
Caragol William JChief Financial Officer
|
GrantOrdinary Shares | 290,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-018504 · ownership.xml · nonDerivative · entry 1 Caragol William J · CIK 0001380465 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,899 F1 · price: Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. F2 · balance_after: 77,899 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 22:16 UTC |
Dreismann HeinrichDirector
|
GrantOrdinary Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-018502 · ownership.xml · nonDerivative · entry 1 Dreismann Heinrich · CIK 0001379372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,700 F1 · price: Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. F2 · balance_after: 19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 22:16 UTC |
Tibbitts Gregory JDirector
|
GrantOrdinary Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-018499 · ownership.xml · nonDerivative · entry 1 Tibbitts Gregory J · CIK 0001326220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,875 F1 · price: Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. F2 · balance_after: 10,875 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 22:15 UTC |
BAECHLER GUIDODirector · Chief Executive Officer
|
GrantOrdinary Shares | 440,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-018497 · ownership.xml · nonDerivative · entry 1 BAECHLER GUIDO · CIK 0001561662 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,058 F1 · price: Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. F2 · balance_after: 6,362 ordinary shares held, and 158,696 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026. Read SEC document |
| February 13, 2026 Filed Mar 3, 2026 15:13 UTC |
Lazar David E.Director
|
GrantSeries C Preferred Shares · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-26-000581 · form412227001_03022026.xml · derivative · entry 4 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 0 shares Expires not disclosed F2 · security: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · security: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F4 · derivative.exercise_price: Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. F2 · price: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · derivative.exercise_date: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F5 · derivative.expiration_date: Each class of Preferred Stock is perpetual and therefore has no expiration date. F3 · derivative.underlying_shares: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Read SEC document |
| February 13, 2026 Filed Mar 3, 2026 15:13 UTC |
Lazar David E.Director
|
GrantSeries B Preferred Shares · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-26-000581 · form412227001_03022026.xml · derivative · entry 3 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 0 shares Expires not disclosed F2 · security: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · security: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F4 · derivative.exercise_price: Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. F2 · price: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · derivative.exercise_date: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F5 · derivative.expiration_date: Each class of Preferred Stock is perpetual and therefore has no expiration date. F3 · derivative.underlying_shares: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Read SEC document |
| February 13, 2026 Filed Mar 3, 2026 15:13 UTC |
Lazar David E.Director
|
GrantSeries A Preferred Shares · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-26-000581 · form412227001_03022026.xml · derivative · entry 2 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Ordinary Shares · 0 shares Expires not disclosed F2 · security: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · security: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F4 · derivative.exercise_price: Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. F2 · price: On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. F3 · derivative.exercise_date: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). F5 · derivative.expiration_date: Each class of Preferred Stock is perpetual and therefore has no expiration date. F3 · derivative.underlying_shares: The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Read SEC document |
| October 17, 2025 Filed Jan 16, 2026 20:42 UTC |
Donahue Kevin Michael10% owner
|
PurchaseCommon Stock | 643,850 | $402,000.00 | $258,827,700,000.00 |
DisclosureSEC source: 0002105585-26-000003 · primary_doc.xml · nonDerivative · entry 1 Donahue Kevin Michael · CIK 0002105585 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 643,850 Read SEC document |
| October 17, 2025 Filed Jan 20, 2026 15:29 UTC Amendment |
Donahue Kevin Michael10% owner
|
PurchaseCommon Stock | 685,000 | $1.51 | $1,034,350.00 |
DisclosureSEC source: 0002105585-26-000005 · primary_doc.xml · nonDerivative · entry 1 Donahue Kevin Michael · CIK 0002105585 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.